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Abstract 
Background: A family history of myocardial infarction (FHMI) has been shown to increase 
the risk of venous thromboembolism (VTE). The mechanism underlying the association 
remains unclear. Therefore, we aimed to determine the risks of myocardial infarction (MI) 
and VTE by FHMI using a cause-specific model, and to explore whether atherosclerotic risk 
factors could explain the association between FHMI and VTE in a population-based cohort. 
Methods and Results: The study included 21 624 subjects recruited from the Tromsø Study in 
1994-95 and 2001-02. Incident MI and VTE events were registered from date of enrollment to 
end of follow-up, December 31, 2010. There were 1 311 MIs and 428 VTEs during a median 
follow-up of 15.8 years. FHMI was associated with a 52% increased risk of MI (adjusted HR 
1.52; 95% CI 1.35-1.70) and a 26% increased risk of VTE (adjusted HR 1.26; 95% CI 1.02-
1.55) in the cause-specific Cox model. Similar results were found using the traditional Cox 
model. The risk estimates by status of FHMI were highest for unprovoked deep vein 
thrombosis (DVT) (adjusted HR 1.69; 95% CI 1.12-2.56), and the risk increased with 
increasing number of affected relatives. Modifiable atherosclerotic risk factors slightly altered 
the association between FHMI and MI, but had a negligible impact on the association between 
FHMI and VTE. 
Conclusions: FHMI was associated with increased risk of both MI and VTE in a cause-
specific model. Apparently, the association between FHMI and VTE applied to unprovoked 
DVT and was not explained by modifiable atherosclerotic risk factors. 
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Introduction 
A family history of myocardial infarction (FHMI) is an established risk factor for myocardial 
infarction (MI), and atherosclerotic risk factors (e.g. smoking, hypertension, 
hypercholesterolemia, obesity and diabetes mellitus) are known to slightly modify the 
association between FHMI and MI.1-5 Recently, FHMI has also been shown to be associated 
with increased risk of venous thromboembolism (VTE).6-9 However, it is uncertain how 
FHMI contributes to the increased risk of VTE. The association may potentially be explained 
by aggregation of common atherosclerotic risk factors, other shared genetic or environmental 
risk factors for MI and VTE, or mediated through a direct impact of MI on VTE risk in 
subjects with FHMI. 
It has been suggested that atherosclerotic risk factors may partly explain the 
association between arterial and venous thrombosis found in observational studies.10-18 
However, growing evidence supports the notion that atherosclerotic risk factors including 
diabetes mellitus, hypertension and dyslipidemia are not associated with VTE.19-23 Obesity 
and advancing age were the only shared risk factors for arterial and venous thrombosis in 
cohort studies investigating the influence of atherosclerotic risk factors on risk of MI and 
VTE within the same population.19, 20 The impact of atherosclerotic risk factors on the 
association between FHMI and risk of VTE remains unsettled. Moreover, to the best of our 
knowledge, no previous study has considered the effect of FHMI on risk of VTE in the 
complete absence of MI in a general population. In a cause-specific model, the impact of MI 
on VTE risk is eliminated, and risks of MI and VTE are estimated in a population with equal 
distribution of exposure and potential unrecognized confounders.  
 We aimed to determine the absolute and relative risks of MI and VTE by FHMI in a 
population-based cohort study, and to explicitly compare the impact of FHMI on risks of MI 
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and VTE by applying a cause-specific model. Moreover, we aimed to explore whether the 




Study participants were recruited from the fourth (1994-95) and fifth survey (2001-02) of the 
Tromsø Study. To these surveys, the entire population (Tromsø 4) or parts (Tromsø 5) of the 
population aged ≥ 25 years living in the municipality of Tromsø, Norway, were invited to 
participate. The overall attendance rate was high, 77% in Tromsø 4 and 79% in Tromsø 5, and 
a total of 27 806 subjects (26 957 subjects from Tromsø 4, and 849 unique subjects from 
Tromsø 5 that did not participate in Tromsø 4) aged 25-97 years participated in at least one of 
the surveys. The study population has been described in detail elsewhere.24 The study was 
approved by the Regional Committee of Medical and Health Research Ethics North Norway, 
and all subjects gave their informed written consent to participate. Subjects who did not 
consent to medical research (n= 222), subjects not officially registered as inhabitants of the 
municipality Tromsø at baseline (n= 45), subjects with VTE (n= 57) or MI (n= 686) before 
baseline, and subjects with missing values of body mass index (BMI), systolic or diastolic 
blood pressure, triglycerides, total cholesterol, high density lipoprotein (HDL), smoking, 
diabetes mellitus or family history of MI before the age of 60 years (n= 5 394) were excluded. 
In total, 21 624 subjects were included and followed from the date of enrollment through the 
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Baseline information was collected by self-administered questionnaires, blood samples and 
physical examinations. Questionnaires were used to obtain information on current smoking, 
physical activity, history of diabetes mellitus or cancer, and family history of MI. To identify 
family history of MI, subjects were asked to report whether their mother, father, sister, 
brother, child, or none in the family had a history of MI before the age of 60 years. A positive 
family history was regarded as ≥ 1 first degree relative with a history of MI before the age of 
60 years. Height, weight, blood pressure, and non-fasting serum lipids were measured as 
previously described.19 BMI was calculated as weight in kilograms divided by the square of 
height in meters (kg/m2). 
 
Registry of VTE  
All first-time VTE events during follow-up were identified by searching the hospital 
discharge diagnosis registry, the autopsy registry, and the radiology procedure registry of the 
University Hospital of North Norway as previously described.25 The medical record for each 
potential VTE case was reviewed by trained personnel, and a VTE event was verified and 
recorded when presence of clinical signs and symptoms of deep vein thrombosis (DVT) or 
pulmonary embolism (PE) were combined with an objective confirmatory radiology 
procedure (compression ultrasonography, venography, spiral computed tomography, 
perfusion-ventilation scan, pulmonary angiography, or autopsy), and resulted in a VTE 
diagnosis that required treatment.25 For patients derived from the autopsy registry, a VTE-
event was recorded when the autopsy record indicated PE as cause of death or as a significant 
condition contributing to death.  
Verified VTE events were classified as unprovoked or provoked based on the presence 
of provoking factors at the time of diagnosis. An event was defined as provoked if one or 
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more of the following factors were present: recent surgery or trauma within the previous 8 
weeks before the event, acute medical conditions (acute MI, stroke or major infectious 
disease), active cancer at the time of the event, marked immobilization (bed rest for > 3 days, 
wheelchair use, or long-distance travel exceeding 4 hours within the last 14 days) or any other 
factor described by a physician in the medical record (e.g. intravascular catheter). 
  
Registry of MI  
Incident events of MI during follow-up were identified by searching the hospital and out-of 
hospital medical records, autopsy records and death certificates, as previously described.19 
The national unique 11-digit identification number allowed linkage to national and local 
diagnosis registries and to the National Causes of Death Registry at Statistics Norway. 
Medical records were case validated by an independent endpoint committee. Modified WHO 
MONICA/MORGAM criteria for myocardial infarction were used and these included clinical 
symptoms and signs, findings in electrocardiograms, values of cardiac biomarkers, and 
autopsy reports when applicable. 
 
Statistical analyses 
In the traditional model, each participant contributed with separate person-years of follow-up 
from (i) the baseline inclusion date (1994-95 or 2001-02) to the date of a diagnosis of MI, the 
date the participant died or moved from the municipality of Tromsø, or until the end of the 
study period (December 31, 2010), and from (ii) the baseline inclusion date to the date of a 
diagnosis of VTE, the date of death or migration, or until the end of the study period. In the 
cause-specific model, person-years for each participant were counted from the date of 
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enrollment to the date of an incident diagnosis of MI or VTE, the date of death or migration, 
or until the end of the study period, whichever came first. All subjects had at most 1 of the 2 
outcomes (i.e. MI or VTE) on the date of first occurrence in the cause-specific model. 
Subjects who died (n=2 359) or moved from Tromsø (n=3 488) during follow-up were 
censored at the date of death or migration. 
Statistical analyses were performed with STATA version 12.0 (Stata Corporation, 
College Station, TX). Crude incidence rates (IR) of MI and VTE were calculated and 
expressed as number of events per 1000 person-years at risk. Cox proportional hazard 
regression models were used to estimate crude and multivariable adjusted hazard ratios (HR) 
with 95 % confidence intervals (CI) for MI, unprovoked and provoked VTE, DVT and PE by 
family history of MI. The multivariable HRs were adjusted for age, sex, BMI, mean systolic 
and diastolic blood pressure, total cholesterol, HDL, triglycerides, self-reported smoking and 
diabetes mellitus. Percent change in the adjusted compared with the crude HR was calculated 
by the formula (100 * (crude HR – adjusted HR) / (crude HR – 1)). Previous studies have 
reported synergistic interaction between FHMI and lipids on risk of MI.2-4 Statistical 
interactions between FHMI and age, sex, BMI, blood pressure, total cholesterol, HDL, 
triglycerides, smoking or diabetes mellitus for MI and VTE were tested by including cross 
product terms in the proportional hazards model. In addition, statistical interactions between 
FHMI and age or sex were tested in analyses with unprovoked DVT as the outcome. The 
proportional hazard assumption was verified by evaluating the parallelism between the curves 
of the log-log survivor function. Furthermore, a test of the proportional hazard assumption 
using Schoenfeld residuals was performed for all the relevant variables. 
Attributable risk (AR%), the proportion of events among the exposed subjects that can 
be explained by the exposure, was calculated from incidence rates of MI, VTE, DVT and PE 
in the population with (Ie) and the population without a family history of MI (I0)  (100% * (Ie - 
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I0) / Ie)). Population attributable risk fraction (PAR%), the proportion of events in the study 
population attributable to the exposure, was calculated using the incidence rates of MI, VTE, 
DVT and PE in the general population (Ip) and in the population without a family history of 
MI (I0)  (100% * (Ip – I0) / Ip ). 
 
Results 
We identified 1 311 subjects with a validated diagnosis of incident MI and 428 subjects with 
an incident VTE event during a median of 15.8 years of follow-up. Characteristics of the 
study participants at baseline are shown in Table 1. Subjects who were diagnosed with VTE 
during follow-up were on average younger, had lower blood pressure, total cholesterol and 
triglyceride levels, higher HDL cholesterol levels, comprised lower proportions of men, 
smokers and subjects with diabetes mellitus, and a higher proportion of subjects with cancer 
than those diagnosed with MI (Table 1). 
Incidence rates and hazard ratios for MI and VTE among subjects with and without 
FHMI are displayed in Table 2. Among subjects with FHMI (n=5 194), 510 MI events (IR 7.5 
per 1000 person-years) and 147 VTE events (IR 2.1  per 1000 person-years) were identified 
during follow-up, while there were 801 MI events (IR 3.7 per 1000 person-years) and 281 
VTE events (IR 1.3 per 1000 person-years) among subjects without FHMI (n=16 430) (Table 
2). Overall, FHMI was associated with a 53% increased risk of MI (adjusted HR 1.53; 95% CI 
1.37-1.71) and a 27% increased risk of VTE (adjusted HR 1.27; 95% CI 1.04-1.56) (Table 2). 
The adjustment for modifiable atherosclerotic risk factors (Table 2, model 2), in addition to 
age and sex, caused a 17% and 8% risk reduction in the risk estimates for MI and VTE, 
respectively. Age, BMI and cholesterol had multiplicative effects with FHMI on the risk of 
MI, whereas no statistical interactions were found with FHMI for VTE or unprovoked DVT. 
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The risk estimates for DVT (adjusted HR 1.29; 95% CI 1.00-1.68) by FHMI were 
somewhat higher than the risk estimates for PE (adjusted HR 1.25; 95% CI 0.91-1.72) in 
stratified analysis (Table 2). Further stratification depending on the presence or absence of 
provoking factors for VTE revealed that the association between and FHMI and VTE was 
confined to unprovoked events, in particular unprovoked DVT. FHMI was associated with a 
45% higher risk of unprovoked VTE (adjusted HR 1.45; 95% CI 1.07-1.97) and a 63% higher 
risk of unprovoked DVT (adjusted HR 1.63; 95% CI 1.08-2.46). There was no significant 
association between FHMI and risk of PE, neither provoked nor unprovoked, in our 
population. 
There were 52 subjects who had both incident MI and incident VTE event during 
follow-up. In order to eliminate the impact of a direct interaction of MI and VTE on the 
apparent associations between FHMI and MI/VTE, we conducted survival analysis in a cause-
specific model. Incidence rates and hazard ratios for the cause-specific survival analysis of MI 
and VTE by FHMI, according to type and number of affected first-degree relatives, are shown 
in Table 3. The risks of VTE by FHMI, and separate entities stratified by location and 
predisposing factors, were similar in the traditional Cox model and in the cause-specific Cox 
model (Tables 2 and 3). The risk estimates for unprovoked VTE events were higher than for 
provoked events. The higher risk estimates for unprovoked events appeared to be driven by a 
strong association between FHMI and unprovoked DVT. FHMI was associated with a 69% 
higher risk of unprovoked DVT (adjusted HR 1.69; 95% CI 1.12-2.56) (Table 3). Adjustment 
for modifiable atherosclerotic risk factors in addition to age and sex did not affect the risk 
estimate. A family history of ≥ 2 subjects with MI increased the risk of unprovoked DVT 
(adjusted HR 2.64; 95% CI 1.12-6.24). A parental history of MI was associated with higher 
risk of VTE than a history of affected siblings. 
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Subjects with ≥ 1 first-degree relative with a history of MI had 1.5-fold higher risk of 
MI (adjusted HR 1.52; 95% CI 1.35-1.70). A parental history of MI was associated with a 
54% increased risk of MI (adjusted HR 1.54; 95% CI 1.34-1.76), while subjects with a sibling 
with a history of MI had a 61% increased risk of MI (adjusted HR 1.61; 95% CI 1.39-1.86). A 
family history of ≥ 2 subjects with MI augmented the risk of MI (adjusted HR 1.85; 95% CI 
1.44-2.36). The risk of MI by FHMI was similar in the traditional Cox model and in the 
cause-specific Cox model (Tables 2 and 3).  
In order to explore whether our assumption that loss to follow-up due to death was 
non-informative, we fit a Fine and Grey proportional subdistribution hazard model to assess 
the impact of treating death as competing risk on the association between FHMI and MI and 
VTE. We reached the same conclusion as that when death was treated as censoring (data not 
shown). 
The attributable risk of MI, total VTE, unprovoked VTE and unprovoked DVT due to 
a family history of MI was 50.1%, 38.0%, 46.5% and 52.6%, respectively. The proportion of 
events in the study population attributed to FHMI (population attributable risk), however, was 




In the present study, subjects with a family history of MI had increased risk of both incident 
myocardial infarction and venous thromboembolism. For VTE, the association with FHMI 
applied to unprovoked events, and appeared to be primarily related to unprovoked deep vein 
thrombosis. Modifiable atherosclerotic risk factors slightly altered the risk of MI associated 
with FHMI, but had a negligible impact on the association between FHMI and VTE. The risk 
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estimates for MI and VTE by FHMI were not affected by a direct interaction between the two 
diseases, and increased with increasing number of affected first-degree relatives. The 
population attributable risks of MI and VTE by FHMI were 19% and 13%, respectively. 
 The increased risk of incident MI associated with FHMI found in our study is in 
agreement with the results of observational studies.1-5 However, our risk estimates for MI 
obtained from a cohort recruited from a general population were lower than those reported in 
previous cohort5 and case-control1-4 studies in which non-fatal MI cases,1, 2 hospitalized 
controls,1, 3, 4 or registered relatives of MI patients5 were included. We also confirmed our 
previous original finding,6 later supported by two independent observational studies7, 9 with 
similar risk estimates for the association between FHMI and VTE, using an extended cohort 
with longer follow-up. 
Modifiable atherosclerotic risk factors including hypertension, dyslipidemia and 
diabetes mellitus are affected by genetic26 and life-style27, 28 factors. In our study, modifiable 
atherosclerotic risk factors influenced the association between FHMI and MI by weakening 
the risk estimates in the multivariable adjusted model. Furthermore, FHMI had a synergistic 
effect with age, BMI and cholesterol on the risk of MI. Environmental factors are therefore 
likely to contribute to the increased risk of MI associated with FHMI. This is further 
supported by the high risk of MI found in subjects reporting ≥ 1 siblings with a history of MI, 
which may be explained by an interaction between shared genes and environmental factors. In 
contrast, modifiable atherosclerotic risk factors only modestly affected the risk of VTE by 
FHMI, and no statistical interactions were found between FHMI and one or more 
atherosclerotic risk factors. Taken together, these findings indicate that atherosclerotic risk 
factors do not explain the observed association between FHMI and VTE, and are in agreement 
with the hypothesis that traditional atherosclerotic risk factors such as diabetes mellitus, 
hypertension, and dyslipidemia do not play an important role in the etiology of VTE.19-23 
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Accordingly, the impact of FHMI on VTE risk has to be mediated through different 
mechanisms potentially including other shared genetic or environmental risk factors. 
The association between FHMI and VTE was mainly attributed to unprovoked VTE 
events. Furthermore, the risk of VTE increased with increasing number of affected relatives 
with a history of MI. Thus, there is strong circumstantial evidence that inherited factors 
contribute to the association between FHMI and VTE. Several genes encoding risk factors for 
VTE are shown to be related to heart disease, and may potentially explain the increased risk 
of VTE in subjects with FHMI. In a genome-wide association study,29 MI was found to be 
associated with the alleles on the ABO locus encoding the highly prevalent non-O blood 
groups,29 which are known to predominantly increase the risk of unprovoked VTE.30, 31 In 
addition, common inherited thrombophilic abnormalities such as factor V Leiden and 
prothrombin G20210A are identified as risk factors for coronary heart disease.32 Factor V 
Leiden is shown to be associated with DVT rather than isolated PE,33 and may explain the 
high risk of unprovoked DVT found in subjects with FHMI. Furthermore, a combination of 
the inherited risk factors related to MI could potentially underlie the association between 
FHMI and VTE, as non-O blood groups and factor V Leiden are found to have an additive 
effect on the risk of VTE.30, 31 Finally, unrecognized genetic variants may partly explain the 
association between FHMI and VTE, which encourage an untargeted approach to reveal novel 
genetic risk factors common for arterial and venous thrombosis. 
It is also possible that the increased risk of VTE found in subjects with FHMI is 
explained by shared environmental risk factors. In a large registry-based study, spouses of MI 
patients were shown to have increased risk of VTE.8 Thus, shared family environment may 
contribute to the observed association between FHMI and VTE. Concordantly, some 
environmental psychosocial factors, such as stress at home and at work and stressful life 
events, have been reported as risk factors for both MI and VTE.34, 35 This is further supported 
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by an observed synergistic effect between job strain and family history of coronary heart 
disease on the risk of MI in women.2 Shared socioeconomic status and diet could potentially 
explain the association between FHMI and VTE. Socioeconomic status including household 
income is found to be inversely associated with coronary heart disease and VTE.21, 36 Diet, 
however, is reported to influence the risks of MI and VTE differently.37, 38 
Numerous observational studies have shown an independent association between 
arterial and venous thrombotic diseases.10-18 However, the risk estimates for MI and VTE by 
FHMI in our study were similar in the traditional Cox model and in the cause-specific Cox 
model, implying that the associations between FHMI and MI and VTE were not affected by a 
direct interaction between VTE and MI. From a public health perspective, we found FHMI to 
be a considerable risk factor for VTE with a predictive value comparable to family history of 
VTE,39 explaining 13% of the VTE events in the study population. Thus, FHMI may be used 
in clinical practice to improve the identification of those at high risk of VTE likely to benefit 
from targeted preventive interventions. 
The main strengths of our study include the prospective design, the large number of 
participants recruited from a general population and the high attendance rate. Moreover, the 
cause-specific model eliminates the impact of MI on risk of VTE, and facilitates risk 
estimation of MI and VTE by FHMI simultaneously in a population with equal distribution of 
potential unrecognized confounders. Conversely, the study has some limitations. Analyses 
were restricted to subjects who had provided information on FHMI. Most likely, the majority 
of subjects with missing information on FHMI (n= 5 038) did not answer this question 
because they did not have a first-degree relative with a history of MI. When we investigated 
the extreme scenarios, i.e. performed analyses under the assumptions that all subjects with 
missing did not have a FHMI, or that all subjects with missing did have a FHMI, the risk 
estimates for MI and VTE did not change notably, which supports our use of complete case 
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analyses. Among those who reported FHMI, over- or underreporting is possible, and this may 
have led to over- or underestimation of the true risk. Underestimation is most likely as a high 
specificity and a lower sensitivity of self-reported FHMI previously has been demonstrated in 
a validation study.40 Furthermore, modifiable atherosclerotic risk factors such as FHMI, 
smoking, diabetes mellitus, hypertension and hypercholesterolemia may change over time, 
and residual confounding by these factors cannot be ruled out. Finally, unrecognized 
confounders may be present, and could potentially explain the observed associations between 
FHMI and MI and VTE. 
In conclusion, subjects with a history of myocardial infarction in a first-degree relative 
before the age of 60 years had increased risk of both incident myocardial infarction and 
venous thromboembolism in a cause-specific model. Apparently, the association between 
FHMI and VTE applied to unprovoked deep vein thrombosis and was not explained by 
modifiable atherosclerotic risk factors. Moreover, the risk of unprovoked DVT increased with 
increasing number of affected first-degree relatives with a history of MI. Our findings support 
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Table 1. Baseline characteristics of participants with subsequent myocardial infarction (MI) or venous thromboembolism (VTE) or no event 
during follow-up, stratified by family history of MI (n = 21 624). The Tromsø Study, 1994-2010. 
 No family history of MI Family history of MI 
 No event 











% (n)/ mean ± SD       
Age (years) 42 ± 13 61 ± 13 57 ± 14 46 ± 13 59 ± 12 58 ± 14 
Sex (male) 46.2 (7 097) 68.3 (547) 49.1 (138) 43.5 (1 984) 57.5 (293) 44.9 (66) 
BMI (kg/m2) 24.8 ± 3.7 26.6 ± 4.1 26.6 ± 4.6 26.4 ± 3.6 26.5 ± 3.7 26.9 ± 4.0 
Systolic BP (mmHg) 131 ± 18 150 ± 24 142 ± 23 134 ± 19 151 ± 23 144 ± 24 
Diastolic BP (mmHg) 76 ± 11 86 ± 14 82 ± 14 79 ± 12 86 ± 13 82 ± 13 
Total cholesterol (mmol/L) 5.78 ± 1.23 6.83 ± 1.24 6.50 ± 1.34 6.20 ± 1.28 6.90 ± 1.21 6.68 ± 1.17 
HDL (mmol/L) 1.51 ± 0.41 1.39 ± 0.38 1.54 ± 0.44 1.50 ± 0.40 1.40 ± 0.40 1.46 ± 0.40 
Triglycerides (mmol/L) 1.45 ± 0.96 1.95 ± 1.19 1.62 ± 0.86 1.58 ± 1.03 1.96 ± 1.16 1.76 ± 1.05 
Diabetes mellitus* 0.9 (137) 4.7 (38) 2.5 (7) 1.5 (69) 6.3 (32) 2.0 (3) 
Cancer* 2.4 (370) 5.2 (42) 7.5 (21) 3.0 (137) 4.1 (21) 9.5 (14) 
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Smoking*† 34.8 (5 350) 43.1 (345) 32.4 (91) 39.8 (1 815) 42.2 (215) 38.8 (57) 
Physical activity*‡ 34.8 (5 356) 21.5 (172) 22.4 (63) 28.9 (1 319) 22.5 (115) 18.4 (27) 
* Self-reported. 
†Daily smoking of cigarettes, cigars or pipe, yes/no. 
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Table 2. Incidence rates (IR) and hazard ratios (HR) with 95 % confidence interval (CI) for myocardial infarction (MI), provoked and 
unprovoked venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) by family history of MI (FHMI) 




Events Crude IR 
(95 % CI)* 
Crude HR 
(95 % CI) 
HR 
(95 % CI)† 
HR 
(95 % CI)‡ 
MI        
No FHMI 215 730 801 3.71 (3.46-3.98)  Ref.  Ref. Ref. 
FHMI 67 726 510 7.53 (6.90-8.21) 2.03 (1.82-2.27) 1.70 (1.52-1.90) 1.53 (1.37-1.71) 
VTE       
All       
No FHMI 217 636 281 1.29 (1.15-1.45)  Ref.  Ref. Ref. 
FHMI 69 355 147 2.12 (1.80-2.49) 1.64 (1.35-2.01) 1.32 (1.08-1.62) 1.27 (1.04-1.56) 
Unprovoked       
No FHMI 216 231 117 0.54 (0.45-0.65) Ref. Ref. Ref. 
FHMI 68 652 68 0.99 (0.78-1.26) 1.83 (1.36-2.47) 1.47 (1.09-1.99) 1.45 (1.07-1.97) 
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Provoked       
No FHMI 216 533 164 0.76 (0.65-0.88) Ref. Ref. Ref. 
FHMI 68 740 79 1.15 (0.92-1.43) 1.52 (1.16-1.99) 1.22 (0.93-1.60) 1.16 (0.88-1.52) 
DVT       
All       
No FHMI 216 515 168 0.8 (0.67-0.90)  Ref.  Ref. Ref. 
FHMI 68 743 88 1.28 (1.04-1.58) 1.65 (1.28-2.14) 1.33 (1.03-1.72) 1.29 (1.00-1.68) 
Unprovoked       
No FHMI 215 616 59 0.27 (0.21-0.35) Ref. Ref. Ref. 
FHMI 68 334 38 0.56 (0.40-0.76) 2.03 (1.35-3.05) 1.63 (1.08-2.46) 1.63 (1.08-2.46) 
Provoked       
No FHMI 216 027 109 0.50 (0.42-0.61) Ref. Ref. Ref. 
FHMI 68 446 50 0.73 (0.55-0.96) 1.45 (1.04-2.02) 1.17 (0.83-1.64) 1.12 (0.80-1.57) 
PE       
All       
No FHMI 216 249 113 0.52 (0.43-0.63)  Ref.  Ref. Ref. 
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FHMI 68 648 59 0.86 (0.67-1.11) 1.65 (1.20-2.26) 1.32 (0.96-1.81) 1.25 (0.91-1.72) 
Unprovoked       
No FHMI 215 743 58 0.27 (0.21-0.35) Ref. Ref. Ref. 
FHMI 68 354 30 0.44 (0.31-0.63) 1.63 (1.05-2.53) 1.31 (0.84-2.05) 1.28 (0.82-2.00) 
Provoked       
No FHMI 215 634 55 0.26 (0.20-0.33) Ref. Ref. Ref. 
FHMI 68 330 29 0.42 (0.19-0.61) 1.67 (1.06-2.62) 1.33 (0.84-2.09) 1.23 (0.78-1.94) 
* Per 1000 person-years.  
† Adjusted for age and sex. 
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Table 3. Incidence rates (IR) and hazard ratios (HR) with 95 % confidence interval (CI) for the cause-specific risk of myocardial infarction (MI), 
provoked and unprovoked venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) by family history of MI 




Events Crude IR 
(95 % CI)* 
Crude HR 
(95 % CI) 
HR 
(95 % CI)† 
HR 
(95 % CI)‡ 
MI       
No FHMI 214 565 768 3.58 (3.33-3.84) Ref. Ref. Ref. 
≥ 1 relative 67 157 482 7.18 (6.56-7.85) 2.01 (1.79-2.25) 1.69 (1.50-1.89) 1.52 (1.35-1.70) 
≥ 2 relatives 4 848 72 14.85 (11.79-18.71) 4.19 (3.29-5.33) 2.39 (1.87-3.05) 1.85 (1.44-2.36) 
Parent 54 791 300 5.48 (4.89-6.13) 1.53 (1.34-1.75) 1.74 (1.52-1.99) 1.54 (1.34-1.76) 
Sibling 16 948 250 14.75 (13.03-16.70) 4.16 (3.61-4.80) 1.81 (1.56-2.10) 1.61 (1.39-1.86) 
VTE       
All       
No FHMI 214 565 267 1.24 (1.10-1.40) Ref. Ref. Ref. 
≥ 1 relative 67 157 134 2.00 (1.68-2.36) 1.61 (1.31-1.98) 1.30 (1.06-1.60) 1.26 (1.02-1.55) 
≥ 2 relatives 4 848 14 2.89 (1.71-4.88) 2.37 (1.38-4.05) 1.36 (0.79-2.34) 1.32 (0.76-2.27) 
Parent 54 791 94 1.72 (1.40-2.10) 1.38 (1.09-1.74) 1.43 (1.13-1.81) 1.36 (1.07-1.73) 
Sibling 16 948 53 3.13 (2.39-4.09) 2.57 (1.91-3.45) 1.15 (0.85-1.56) 1.12 (0.83-1.52) 
Unprovoked       
No FHMI 213 275 114 0.53 (0.44-0.64) Ref. Ref. Ref. 
≥ 1 relative 66 552 66 0.99 (0.78-1.26) 1.86 (1.38-2.52) 1.51 (1.12-2.05) 1.49 (1.09-2.02) 
≥ 2 relatives 4 795 8 1.67 (0.83-3.34) 3.20 (1.56-6.55) 1.79 (0.87-3.69) 1.86 (0.90-3.86) 
Parent 54 384 49 0.90 (0.68-1.19) 1.68 (1.20-2.35) 1.73 (1.24-2.42) 1.68 (1.20-2.36) 
Sibling 16 698 25 1.50 (1.01-2.22) 2.88 (1.86-4.43) 1.29 (0.82-2.01) 1.30 (0.83-2.04) 
Provoked       
No FHMI 213 500 153 0.72 (0.61-0.84) Ref. Ref. Ref. 
≥ 1 relative 66 569 68 1.02 (0.81-1.30) 1.43 (1.08-1.91) 1.15 (1.86-1.53) 1.10 (0.82-1.47) 
≥ 2 relatives 4 779 6 1.26 (0.56-2.79) 1.78 (0.79-4.02) 1.03 (0.46-2.34) 0.95 (0.42-2.15) 
Parent 54 333 45 0.83 (0.62-1.11) 1.16 (0.83-1.61) 1.21 (0.87-1.69) 1.13 (0.81-1.59) 
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Sibling 16 749 28 1.67 (1.15-2.42) 2.38 (1.59-3.55) 1.05 (0.69-1.59) 1.01 (0.66-1.52) 
DVT        
All       
No FHMI 213 518 161 0.75 (0.65-0.88) Ref. Ref. Ref. 
≥ 1 relative 66 631 84 1.26 (1.02-1.56) 1.68 (1.29-2.18) 1.35 (1.04-1.77) 1.32 (1.01-1.73) 
≥ 2 relatives 4 809 10 2.08 (1.12-3.86) 2.78 (1.47-5.27) 1.61 (0.85-3.06) 1.52 (0.80-2.90) 
Parent 54 401 58 1.07 (0.82-1.38) 1.41 (1.05-1.91) 1.46 (1.08-1.98) 1.41 (1.04-1.91) 
Sibling 16 773 35 2.09 (1.50-2.91) 2.80 (1.94-4.03) 1.26 (0.87-1.85) 1.23 (0.84-1.79) 
Unprovoked        
No FHMI 212 684 58 0.27 (0.21-0.35) Ref. Ref. Ref. 
≥ 1 relative 66 262 38 0.57 (0.42-0.79) 2.11 (1.40-3.17) 1.70 (1.13-2.57) 1.69 (1.12-2.56) 
≥ 2 relatives 4 777 6 1.26 (0.56-2.80) 4.64 (2.00-10.76) 2.53 (1.08-5.91) 2.64 (1.12-6.24) 
Parent 54 145 27 0.50 (0.34-0.73) 1.83 (1.16-2.89) 1.88 (1.19-2.96) 1.83 (1.16-2.91) 
Sibling 16 630 17 1.02 (0.64-1.64) 3.78 (2.20-6.50) 1.67 (0.95-2.93) 1.68 (0.96-2.96) 
Provoked       
No FHMI 213 044 103 0.48 (0.40-0.59) Ref. Ref. Ref. 
≥ 1 relative 66 334 46 0.69 (0.52-0.93) 1.44 (1.02-2.03) 1.16 (0.82-1.65) 1.12 (0.79-1.60) 
≥ 2 relatives 4 758 4 0.84 (0.32-2.24) 1.75 (0.65-4.76) 1.05 (0.38-2.85) 0.93 (0.34-2.55) 
Parent 54 183 31 0.57 (0.40-0.81) 1.18 (0.79-1.77) 1.23 (0.82-1.84) 1.17 (0.78-1.75) 
Sibling 16 643 18 1.08 (0.68-1.72) 2.26 (1.37-3.73) 1.03 (0.62-1.73) 0.99 (0.59-1.66) 
PE       
All       
No FHMI 213 256 106 0.50 (0.41-0.60)  Ref.  Ref. Ref. 
≥ 1 relative 66 490 50 0.75 (0.57-0.99) 1.52 (1.09-2.13) 1.23 (0.87-1.72) 1.17 (0.83-1.64) 
≥ 2 relatives 4 765 4 0.84 (0.32-2.24) 1.75 (0.64-4.75) 0.98 (0.36-2.67) 0.97 (0.36-2.67) 
Parent 54 316 36 0.66 (0.48-0.92) 1.33 (0.91-1.94) 1.39 (0.95-2.04) 1.30 (0.89-1.91) 
Sibling 16 675 18 1.08 (0.68-1.71) 2.26 (1.37-3.72) 0.98 (0.59-1.64) 0.96 (0.57-1.61) 
Unprovoked       
No FHMI 212 800 56 0.26 (0.20-0.34)  Ref.  Ref. Ref. 
≥ 1 relative 66 255 28 0.42 (0.29-0.61) 1.61 (1.03-2.54) 1.32 (0.84-2.08) 1.28 (0.81-2.02) 
≥ 2 relatives 4 744 2 0.42 (0.11-1.69) 1.67 (0.41-6.84) 0.96 (0.23-3.94) 1.00 (0.24-4.14) 
Parent 54 165 22 0.41 (0.27-0.62) 1.54 (0.94-2.52) 1.59 (0.97-2.60) 1.53 (0.93-2.51) 
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Sibling 16 568 8 0.48 (0.24-0.97) 1.92 (0.91-2.03) 0.87 (0.40-1.85) 0.88 (0.41-1.89) 
Provoked       
No FHMI 212 665 50 0.24 (0.18-0.31) Ref. Ref. Ref. 
≥ 1 relative 66 200 22 0.33 (0.22-0.50) 1.43 (0.86-2.36) 1.13 (0.68-1.87) 1.05 (0.63-1.75) 
≥ 2 relatives 4 748 2 0.42 (0.11-0.17) 1.84 (0.45-7.57) 1.00 (0.24-4.14) 0.94 (0.23-3.93) 
Parent 54 077 14 0.26 (0.15-0.44) 1.10 (0.61-2.00) 1.18 (0.65-2.14) 1.07 (0.59-1.94) 
Sibling 16 606 10 0.60 (0.32-1.12) 2.65 (1.34-5.22) 1.10 (0.55-2.20) 1.04 (0.51-2.09) 
* Per 1000 person-years.  
† Adjusted for age and sex. 
‡ Adjusted for age, sex, BMI, mean systolic blood pressure, mean diastolic blood pressure, cholesterol, HDL, triglycerides, diabetes mellitus and 
smoking. 
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